R'Keon Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
as on 16-11-2024
- Paid Up Capital ₹ 1.06 Cr
as on 16-11-2024
- Company Age 6 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 2.14 Cr
as on 16-11-2024
- Revenue 7.66%
(FY 2023)
- Profit -31.92%
(FY 2023)
- Ebitda -22.65%
(FY 2023)
- Net Worth 145.89%
(FY 2023)
- Total Assets 6.40%
(FY 2023)
About R'Keon Life Sciences
The Corporate was formerly known as Optho Life Sciences Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 1.06 Cr.
The company has closed loans amounting to ₹2.14 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Rakesh Agarwal, Ridim Agarwal, and Ratna Agarwal serve as directors at the Company.
- CIN/LLPIN
U85100UP2018PTC108707
- Company No.
108707
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Sep 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Allahabad, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does R'keon Life Sciences Private Limited offer?
R'Keon Life Sciences Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Multivitamin Tablets & Capsules, Health Conditions, Cold & Cough.
Who are the key members and board of directors at R'Keon Life Sciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rakesh Agarwal  | Director | 30-Sep-2018 | Current |
| Ridim Agarwal | Director | 30-Sep-2018 | Current |
| Ratna Agarwal | Director | 24-Oct-2020 | Current |
Financial Performance of R'Keon Life Sciences.
R'Keon Life Sciences Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 7.66% increase. The company also saw a substantial fall in profitability, with a 31.92% decrease in profit. The company's net worth Soared by an impressive increase of 145.89%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of R'Keon Life Sciences?
In 2023, R'Keon Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 04 Jun 2019 | ₹2.14 Cr | Satisfied |
How Many Employees Work at R'Keon Life Sciences?
R'Keon Life Sciences has a workforce of 158 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of R'Keon Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped R'Keon Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
